Carregant...
New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1
Immunotherapy has significantly altered the treatment landscape for many cancers, including non-small cell lung cancer (NSCLC). Currently approved immuno-oncology agents for lung cancer are aimed at the reversal of immune checkpoints, programmed death protein-1 (PD-1) and programmed death ligand-1 (...
Guardat en:
| Publicat a: | Ther Adv Respir Dis |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6144513/ https://ncbi.nlm.nih.gov/pubmed/30215300 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1753466618794133 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|